Oral cyclosporine treatment in dogs: A review of the literature

Journal of Veterinary Internal Medicine

Volumn 28, Issue 1, 2014, Pages 1-20

  Archer, T M ^a   Boothe, D M ^b   Langston, V C ^a   Fellman, C L ^a   Lunsford, K V ^a   Mackin, A J ^a  

^a MISSISSIPPI STATE UNIVERSITY   (United States)

^b AUBURN UNIVERSITY   (United States)

Author keywords

Cyclosporine; Pharmacodynamics; Pharmacokinetics; Therapeutic drug monitoring

Indexed keywords

ANIMALIA; CANIS FAMILIARIS;

CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT;

ANIMAL; ANIMAL DISEASE; AUTOIMMUNE DISEASE; BIOAVAILABILITY; DOG; DOG DISEASE; DRUG MONITORING; IMMUNOLOGY; ORAL DRUG ADMINISTRATION; PHARMACODYNAMICS; PHARMACOKINETICS; REVIEW;

CYCLOSPORINE; PHARMACODYNAMICS; PHARMACOKINETICS; THERAPEUTIC DRUG MONITORING;

ADMINISTRATION, ORAL; ANIMALS; AUTOIMMUNE DISEASES; BIOLOGICAL AVAILABILITY; CYCLOSPORINE; DOG DISEASES; DOGS; IMMUNOSUPPRESSIVE AGENTS;

EID: 84892479358     PISSN: 08916640     EISSN: 19391676     Source Type: Journal    
DOI: 10.1111/jvim.12265     Document Type: Review

References (114)

1. Tedesco D, Haragsim L. Cyclosporine: A review. J Transplant 2012;2012:230386.
2. Kahan BD. Therapeutic drug monitoring of cyclosporine: 20 years of progress. Transplant Proc 2004;36:378S-391S.
3. Calne R. Cyclosporine as a milestone in immunosuppression. Transplant Proc 2004;36:13S-15S.
4. Graeb C, Arbogast H, Guba M, et al. Cyclosporine: 20 years of experience at the University of Munich. Transplant Proc 2004;36:125S-129S.
5. Citterio F. Evolution of the therapeutic drug monitoring of cyclosporine. Transplant Proc 2004;36:420S-425S.
6. Kapturczak MH, Meier-Kriesche HU, Kaplan B. Pharmacology of calcineurin antagonists. Transplant Proc 2004;36:25S-32S.
7. Kadar E, Sykes JE, Kass PH, et al. Evaluation of the prevalence of infections in cats after renal transplantation: 169 cases (1987-2003). J Am Vet Med Assoc 2005;227:948-953.
8. Mathews KA, Holmberg DL. Kidney transplantation in dogs with naturally occurring end-stage renal disease. J Am Anim Hosp Assoc 2000;36:475.
9. Kyles AE, Gregory CR, Griffey SM, et al. An evaluation of combined immunosuppression with MNA 715 and microemulsified cyclosporine on renal allograft rejection in mismatched mongrel dogs. Vet Surg 2002;31:358-366.
10. Bernsteen L, Gregory CR, Kyles AE, et al. Microemulsified cyclosporine-based immunosuppression for the prevention of acute renal allograft rejection in unrelated dogs: Preliminary experimental study. Vet Surg 2003;32:213-219.
11. Allenspach K, Rufenacht S, Sauter S, et al. Pharmacokinetics and clinical efficacy of cyclosporine treatment of dogs with steroid-refractory inflammatory bowel disease. J Vet Intern Med 2006;20:239-244.
12. Olivry T, Rivierre C, Murphy KM. Efficacy of cyclosporine for treatment induction of canine pemphigus foliaceus. Vet Rec 2003;152:53-54.
13. Mathews KA, Sukhiani HR. Randomized controlled trial of cyclosporine for treatment of perianal fistulas in dogs. J Am Vet Med Assoc 1997;211:1249-1253.
14. Gnirs K. Ciclosporin treatment of suspected granulomatous meningoencephalomyelitis in three dogs. J Small Anim Pract 2006;47:201-206.
15. Boothe DM. Therapeutic drug monitoring. Boothe DM, ed. Small Animal Clinical Pharmacology and Therapeutics. St. Louis, MO: Elsevier; 2012:112-127.
16. Gregory C. Current veterinary therapy XIV. Bonagura JD, ed. Immunosuppressive Agents. St. Louis, MO: Saunders Elsevier; 2009:2.
17. Kovarik JM, Mueller EA, van Bree JB, et al. Reduced inter- and intraindividual variability in cyclosporine pharmacokinetics from a microemulsion formulation. J Pharm Sci 1994;83:444-446.
18. Mueller EA, Kovarik JM, van Bree JB, et al. Improved dose linearity of cyclosporine pharmacokinetics from a microemulsion formulation. Pharm Res 1994;11:301-304.
19. Jorga A, Holt DW, Johnston A. Therapeutic drug monitoring of cyclosporine. Transplant Proc 2004;36:396S-403S.
20. Rao A, Luo C, Hogan PG. Transcription factors of the NFAT family: Regulation and function. Annu Rev Immunol 1997;15:707-747.
21. Rovira P, Mascarell L, Truffa-Bachi P. The impact of immunosuppressive drugs on the analysis of T cell activation. Curr Med Chem 2000;7:673-692.
22. Murphy K, Travers P, Walport M. Janeway's Immunobiology, 7th ed. New York, NY: Garland Science; 2008.
23. Robson D. Review of the properties and mechanisms of action of cyclosporine with an emphasis on dermatological therapy in dogs, cats and people. Vet Rec 2003;152:768-772.
24. Patricelli AJ, Hardie RJ, McAnulty JE. Cyclosporine and ketoconazole for the treatment of perianal fistulas in dogs. J Am Vet Med Assoc 2002;220:1009-1016.
25. Robson D. Review of the pharmacokinetics, interactions and adverse reactions of cyclosporine in people, dogs and cats. Vet Rec 2003;152:739-748.
26. Plumb DC. Plumb's Veterinary Drug Handbook, 6th ed. Ames, IA: PharmaVet Inc.; 2008:5.
27. Guaguere E, Steffan J, Olivry T. Cyclosporin A: A new drug in the field of canine dermatology. Vet Dermatol 2004;15:61-74.
28. Steffan J, Strehlau G, Maurer M, et al. Cyclosporin A pharmacokinetics and efficacy in the treatment of atopic dermatitis in dogs. J Vet Pharmacol Ther 2004;27:231-238.
29. Thelen A, Mueller RS, Linek M, et al. Influence of food intake on the clinical response to cyclosporin A in canine atopic dermatitis. Vet Rec 2006;159:854-856.
30. Lown KS, Mayo RR, Leichtman AB, et al. Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine. Clin Pharmacol Ther 1997;62:248-260.
31. Mealey KL, Waiting D, Raunig DL, et al. Oral bioavailability of P-glycoprotein substrate drugs do not differ between ABCB1-1Delta and ABCB1 wild type dogs. J Vet Pharmacol Ther 2010;33:453-460.
32. Daigle JC, Hosgood G, Foil CS, et al. Effect of cimetidine on pharmacokinetics of orally administered cyclosporine in healthy dogs. Am J Vet Res 2001;62:1046-1050.
33. Whalen RD, Tata PN, Burckart GJ, et al. Species differences in the hepatic and intestinal metabolism of cyclosporine. Xenobiotica 1999;29:3-9.
34. Vickers AE, Fischer V, Connors S, et al. Cyclosporin A metabolism in human liver, kidney, and intestine slices. Comparison to rat and dog slices and human cell lines. Drug Metab Dispos 1992;20:802-809.
35. D'Mello A, Venkataramanan R, Satake M, et al. Pharmacokinetics of the cyclosporine-ketoconazole interaction in dogs. Res Commun Chem Pathol Pharmacol 1989;64:441-454.
36. Dahlinger J, Gregory C, Bea J. Effect of ketoconazole on cyclosporine dose in healthy dogs. Vet Surg 1998;27:64-68.
37. Katayama M, Igarashi H, Fukai K, et al. Fluconazole decreases cyclosporine dosage in renal transplanted dogs. Res Vet Sci 2010;89:124-125.
38. Katayama M, Igarashi H, Tani K, et al. Effect of multiple oral dosing of fluconazole on the pharmacokinetics of cyclosporine in healthy beagles. J Vet Med Sci 2008;70:85-88.
39. D'Souza MJ, Pollock SH, Solomon HM. Cyclosporine-cimetidine interaction. Drug Metab Dispos 1988;16:57-59.
40. Bar-Meir S, Bardan E, Ronen I, et al. Cimetidine and omeprazole do not affect cyclosporine disposition by the rat liver. Eur J Drug Metab Pharmacokinet 1993;18:355-358.
41. Shaefer MS, Rossi SJ, McGuire TR, et al. Evaluation of the pharmacokinetic interaction between cimetidine or famotidine and cyclosporine in healthy men. Ann Pharmacother 1995;29:1088-1091.
42. Radwanski NE, Cerundolo R, Shofer FS, et al. Effects of powdered whole grapefruit and metoclopramide on the pharmacokinetics of cyclosporine in dogs. Am J Vet Res 2012;72:687-693.
43. Alkharfy KM. Influence of overt diabetes mellitus on cyclosporine pharmacokinetics in a canine model. Exp Diabetes Res 2009;2009:363787.
44. White JV, Ravis WR, Nachreiner R, et al. Cyclosporine pharmacokinetics in normal and pancreatectomized dogs. Transplantation 1986;42:390-395.
45. Takaya S, Iwatsuki S, Noguchi T, et al. The influence of liver dysfunction on cyclosporine pharmacokinetics-A comparison between 70 per cent hepatectomy and complete bile duct ligation in dogs. Jpn J Surg 1989;19:49-56.
46. Patterson AP, Campbell KL. Managing anal furunculosis in dogs. Compendium 2005;27:339-355.
47. Singh AK. Narsipur SS. Cyclosporine A: Commentary on brand versus generic formulation exchange. J Transplant 2011;2011:480642.
48. Hibberd AD, Trevillian PR, Roger SD, et al. Assessment of the bioequivalence of a generic cyclosporine A by a randomized controlled trial in stable renal recipients. Transplantation 2006;81:711-717.
49. Fukunaga K, Orito K. Time-course effects of St John's wort on the pharmacokinetics of cyclosporine in dogs: Interactions between herbal extracts and drugs. J Vet Pharmacol Ther 2011;35:446-451.
50. Lai J, Lu Y, Yin Z, et al. Pharmacokinetics and enhanced oral bioavailability in Beagle dogs of cyclosporine A encapsulated in glyceryl monooleate/poloxamer 407 cubic nanoparticles. Int J Nanomedicine 2010;5:13-23.
51. Sander C, Holm P. Porous magnesium aluminometasilicate tablets as carrier of a cyclosporine self-emulsifying formulation. AAPS PharmSciTech 2009;10:1388-1395.
52. Amatori FM, Meucci V, Giusiani M, et al. Effect of grapefruit juice on the pharmacokinetics of cyclosporine in dogs. Vet Rec 2004;154:180-181.
53. El-Shabouri MH. Positively charged nanoparticles for improving the oral bioavailability of cyclosporin-A. Int J Pharm 2002;249:101-108.
54. Fischer JR, Harkin KR, Freeman LC. Concurrent administration of water-soluble vitamin E can increase the oral bioavailability of cyclosporine A in healthy dogs. Vet Ther 2002;3:465-473.
55. Ford J, Woolfe J, Florence AT. Nanospheres of cyclosporin A: Poor oral absorption in dogs. Int J Pharm 1999;183:3-6.
56. Griffiths LG, Sullivan M, Borland WW. Cyclosporin as the sole treatment for anal furunculosis: Preliminary results. J Small Anim Pract 1999;40:569-572.
57. Yang SG. Biowaiver extension potential and IVIVC for BCS Class II drugs by formulation design: Case study for cyclosporine self-microemulsifying formulation. Arch Pharm Res 2010;33:1835-1842.
58. Steffan J, Parks C, Seewald W. Clinical trial evaluating the efficacy and safety of cyclosporine in dogs with atopic dermatitis. J Am Vet Med Assoc 2005;226:1855-1863.
59. Olivry T, Steffan J, Fisch RD, et al. Randomized controlled trial of the efficacy of cyclosporine in the treatment of atopic dermatitis in dogs. J Am Vet Med Assoc 2002;221:370-377.
60. Seibel W, Yahia NA, McCleary LB, et al. Cyclosporine-induced gingival overgrowth in Beagle dogs. J Oral Pathol Med 1989;18:240-245.
61. Werner AH. Psoriasiform-lichenoid-like dermatosis in three dogs treated with microemulsified cyclosporine A. J Am Vet Med Assoc 1986;2003:1013-1016.
62. Favrot C, Olivry T, Werner AH, et al. Evaluation of papillomaviruses associated with cyclosporine-induced hyperplastic verrucous lesions in dogs. Am J Vet Res 2005;66:1764-1769.
63. Radowicz SN, Power HT. Long-term use of cyclosporine in the treatment of canine atopic dermatitis. Vet Dermatol 2005;16:81-86.
64. Mohri T, Takashima K, Yamane T, et al. Purulent pericarditis in a dog administered immune-suppressing drugs. J Vet Med Sci 2009;71:669-672.
65. Galgut BI, Janardhan KS, Grondin TM, et al. Detection of Neospora caninum tachyzoites in cerebrospinal fluid of a dog following prednisone and cyclosporine therapy. Vet Clin Pathol 2010;39:386-390.
66. Blackwood L, German AJ, Stell AJ, et al. Multicentric lymphoma in a dog after cyclosporine therapy. J Small Anim Pract 2004;45:259-262.
67. Callan MB, Preziosi D, Mauldin E. Multiple papillomavirus-associated epidermal hamartomas and squamous cell carcinomas in situ in a dog following chronic treatment with prednisone and cyclosporine. Vet Dermatol 2005;16:338-345.
68. Wahlstrom HE, Lavelle-Jones M, Endres D, et al. Inhibition of insulin release by cyclosporine and production of peripheral insulin resistance in the dog. Transplantation 1990;49:600-604.
69. Wahlstrom HE, Akimoto R, Endres D, et al. Recovery and hypersecretion of insulin and reversal of insulin resistance after withdrawal of short-term cyclosporine treatment. Transplantation 1992;53:1190-1195.
70. Thacker EL. Immunomodulators, immunostimulants, and immunotherapies in small animal veterinary medicine. Vet Clin North Am Small Anim Pract 2010;40:473-483.
71. Rodriguez-Romo R, Morales-Buenrostro LE, Lecuona L, et al. Immune response after rabies vaccine in a kidney transplant recipient. Transpl Infect Dis 2011;13:492-495.
72. Cramer CH, Shieck V, Thomas SE, et al. Immune response to rabies vaccination in pediatric transplant patients. Pediatr Transplant 2008;12:874-877.
73. Mathews KA, Holmberg DL, Johnston K, et al. Renal allograft survival in outbred mongrel dogs using rabbit anti-dog thymocyte serum in combination with immunosuppressive drug therapy with or without donor bone marrow. Vet Surg 1994;23:347-357.
74. Steffan J, Alexander D, Brovedani F, et al. Comparison of cyclosporine A with methylprednisolone for treatment of canine atopic dermatitis: A parallel, blinded, randomized controlled trial. Vet Dermatol 2003;14:11-22.
75. Fontaine J, Olivry T. Treatment of canine atopic dermatitis with cyclosporine: A pilot clinical study. Vet Rec 2001;148:662-663.
76. Olivry T, Rivierre C, Jackson HA, et al. Cyclosporine decreases skin lesions and pruritus in dogs with atopic dermatitis: A blinded randomized prednisolone-controlled trial. Vet Dermatol 2002;13:77-87.
77. Linek M, Boss C, Haemmerling R, et al. Effects of cyclosporine A on clinical and histologic abnormalities in dogs with sebaceous adenitis. J Am Vet Med Assoc 2005;226:59-64.
78. Mouatt JG. Cyclosporin and ketoconazole interaction for treatment of perianal fistulas in the dog. Aust Vet J 2002;80:207-211.
79. O'Neill T, Edwards GA, Holloway S. Efficacy of combined cyclosporine A and ketoconazole treatment of anal furunculosis. J Small Anim Pract 2004;45:238-243.
80. House AK, Guitian J, Gregory SP, et al. Evaluation of the effect of two dose rates of cyclosporine on the severity of perianal fistulae lesions and associated clinical signs in dogs. Vet Surg 2006;35:543-549.
81. Hardie RJ, Gregory SP, Tomlin J, et al. Cyclosporine treatment of anal furunculosis in 26 dogs. J Small Anim Pract 2005;46:3-9.
82. Doust R, Griffiths LG, Sullivan M. Evaluation of once daily treatment with cyclosporine for anal furunculosis in dogs. Vet Rec 2003;152:225-229.
83. Adamo FP, O'Brien RT. Use of cyclosporine to treat granulomatous meningoencephalitis in three dogs. J Am Vet Med Assoc 2004;225:1196.
84. Stein CM, Murray JJ, Wood AJ. Inhibition of stimulated interleukin-2 production in whole blood: A practical measure of cyclosporine effect. Clin Chem 1999;45:1477-1484.
85. Oellerich M, Barten MJ, Armstrong VW. Biomarkers: The link between therapeutic drug monitoring and pharmacodynamics. Ther Drug Monit 2006;28:35-38.
86. Bohler T, Nolting J, Kamar N, et al. Validation of immunological biomarkers for the pharmacodynamic monitoring of immunosuppressive drugs in humans. Ther Drug Monit 2007;29:77-86.
87. Gilger BC, Andrews J, Wilkie DA, et al. Cellular immunity in dogs with keratoconjunctivitis sicca before and after treatment with topical 2% cyclosporine. Vet Immunol Immunopathol 1995;49:199-208.
88. Williams DL. Lack of effects on lymphocyte function from chronic topical ocular cyclosporine medication: A prospective study. Vet Ophthalmol 2010;13:315-320.
89. Brignole F, Pisella PJ, De Saint Jean M, et al. Flow cytometric analysis of inflammatory markers in KCS: 6-month treatment with topical cyclosporin A. Invest Ophthalmol Vis Sci 2001;42:90-95.
90. Kobayashi T, Momoi Y, Iwasaki T. Cyclosporine A inhibits the mRNA expressions of IL-2, IL-4 and IFN-gamma, but not TNF-alpha, in canine mononuclear cells. J Vet Med Sci 2007;69:887-892.
91. Tivers MS, Catchpole B, Gregory SP, et al. Interleukin-2 and interferon-gamma mRNA expression in canine anal furunculosis lesions and the effect of ciclosporin therapy. Vet Immunol Immunopathol 2008;125:31-36.
92. Fellman CL, Stokes JV, Archer TM, et al. Cyclosporine A affects the in vitro expression of T cell activation-related molecules and cytokines in dogs. Vet Immunol Immunopathol 2011;140:175-180.
93. Archer TM, Fellman CL, Stokes JV, et al. Pharmacodynamic monitoring of canine T-cell cytokine responses to oral cyclosporine. J Vet Intern Med 2011;25:1391-1397.
94. Olivry T, DeBoer DJ, Favrot C, et al. Treatment of canine atopic dermatitis: 2010 clinical practice guidelines from the International Task Force on Canine Atopic Dermatitis. Vet Dermatol 2010;21:233-248.
95. Steffan J, Favrot C, Mueller R. A systematic review and meta-analysis of the efficacy and safety of cyclosporin for the treatment of atopic dermatitis in dogs. Vet Dermatol 2006;17:3-16.
96. Kovalik M, Taszkun I, Pomorski Z, et al. Evaluation of a human generic formulation of ciclosporin in the treatment of canine atopic dermatitis with in vitro assessment of the functional capacity of phagocytic cells. Vet Rec 2011;168:537.
97. Gomez SM, Morris DO, Rosenbaum MR, et al. Outcome and complications associated with treatment of pemphigus foliaceus in dogs: 43 cases (1994-2000). J Am Vet Med Assoc 2004;224:1312-1316.
98. Kovalik M, Thoday KL, van den Broek AH. The use of ciclosporin A in veterinary dermatology. Vet J 2012;193:317-325.
99. Fogle JE, Bissett SA. Mucosal immunity and chronic idiopathic enteropathies in dogs. Compend Contin Educ Vet 2007;29:290-302; quiz 306.
100. Bexfield NH, Watson PJ, Herrtage ME. Management of myasthenia gravis using cyclosporine in 2 dogs. J Vet Intern Med 2006;20:1487-1490.
101. Adamo PF, Adams WM, Steinberg H. Granulomatous meningoencephalomyelitis in dogs. Compend Contin Educ Vet 2007;29:678-690.
102. Higginbotham MJ, Kent M, Glass EN. Noninfectious inflammatory central nervous system diseases in dogs. Compend Contin Educ Vet 2007;29:488-497; quiz 497, 501.
103. Talarico LR, Schatzberg SJ. Idiopathic granulomatous and necrotising inflammatory disorders of the canine central nervous system: A review and future perspectives. J Small Anim Pract 2009;51:138-149.
104. Adamo PF, Rylander H, Adams WM. Ciclosporin use in multi-drug therapy for meningoencephalomyelitis of unknown aetiology in dogs. J Small Anim Pract 2007;48:486-496.
105. Gregory CR, Kyles AE, Bernsteen L, et al. Results of clinical renal transplantation in 15 dogs using triple drug immunosuppressive therapy. Vet Surg 2006;35:105-112.
106. Collier DS, Calne RY, De Curtins M, et al. Alternate-day cyclosporine A and azathioprine in experimental dog renal allografts. Transplant Proc 1987;19:1279-1280.
107. Ochiai T, Sakamoto K, Gunji Y, et al. Effects of combination treatment with FK506 and cyclosporine on survival time and vascular changes in renal-allograft-recipient dogs. Transplantation 1989;48:193-197.
108. Kyles AE, Gregory CR, Griffey SM, et al. Immunosuppression with a combination of the leflunomide analog, FK778, and microemulsified cyclosporine for renal transplantation in mongrel dogs. Transplantation 2003;75:1128-1133.
109. Finco DR, Rawlings CA, Crowell WA, et al. Efficacy of azathioprine versus cyclosporine on kidney graft survival in transfused and nontransfused unmatched mongrel dogs. J Vet Intern Med 1987;1:61-66.
110. Grundy SA, Barton C. Influence of drug treatment on survival of dogs with immune-mediated hemolytic anemia: 88 cases (1989-1999). J Am Vet Med Assoc 2001;218:543-546.
111. O'Marra SK, Delaforcade AM, Shaw SP. Treatment and predictors of outcome in dogs with immune-mediated thrombocytopenia. J Am Vet Med Assoc 2011;238:346-352.
112. Miller MD, Lunn KF. Diagnostic use of cytologic examination of bone marrow from dogs with thrombocytopenia: 58 cases (1994-2004). J Am Vet Med Assoc 2007;231:1540-1544.
113. Putsche JC, Kohn B. Primary immune-mediated thrombocytopenia in 30 dogs (1997-2003). J Am Anim Hosp Assoc 2008;44:250-257.
114. Clements DN, Gear RN, Tattersall J, et al. Type I immune-mediated polyarthritis in dogs: 39 cases (1997-2002). J Am Vet Med Assoc 2004;224:1323-1327.